Overview
Nanobiotix is a Paris-based clinical-stage biotech company developing a genuinely novel cancer treatment modality — radiation enhancement therapy using hafnium oxide nanoparticles — that represents France’s most advanced commercial nanomedicine program. Founded in 2003 by Laurent Lévy, the company has spent over two decades developing NBTXR3, a product that consists of crystalline hafnium oxide nanoparticles injected directly into solid tumors before standard radiotherapy treatment. When the tumor is irradiated, the nanoparticles amplify the local radiation dose within the tumor while leaving surrounding healthy tissue relatively unaffected, potentially improving tumor control rates while reducing the systemic side effects of conventional radiotherapy dose escalation.
The company is dual-listed on Euronext Paris and the Nasdaq exchange (NBTX), reflecting its ambition to compete in both European and US oncology markets — and making it one of the few French biotech companies to achieve Nasdaq listing, a significant commercial milestone. Its strategic partnership with Janssen (Johnson & Johnson’s pharmaceutical arm), announced in 2019 for approximately $60 million in upfront and milestone payments, provides both commercial validation and development support for NBTXR3 across multiple tumor indications including head and neck cancer, rectal cancer, liver cancer, and lung cancer. This partnership structure — retaining most pipeline rights while receiving development funding — is a model France 2030’s health innovation programs explicitly seek to replicate across the French biotech sector.
NBTXR3 has received European regulatory approval for locally advanced soft tissue sarcoma, a rare cancer with limited treatment options, making it the world’s first approved radioenhancer. This approval milestone — achieved entirely by a French company with technology invented and developed in France — is the type of regulatory success France 2030 targets in its health innovation agenda: not merely conducting research but bringing it through clinical development to commercial reality. The company’s clinical pipeline extends to much larger patient populations including prostate cancer, where NBTXR3’s ability to enhance brachytherapy or external beam radiotherapy without increasing systemic toxicity is being evaluated.
France 2030 Funding & Projects
Nanobiotix’s development has been supported by successive generations of French public investment programs — from early ANR (Agence Nationale de la Recherche) grants through multiple PIA (Programme d’Investissements d’Avenir) funding rounds and now through France 2030’s health innovation pillar. Bpifrance has been a consistent financial backer, both through direct equity investment (Bpifrance Investissement has held shares in Nanobiotix since early stages) and through repayable advance mechanisms that provided non-dilutive development funding for NBTXR3 clinical trials.
France 2030 specifically identifies nanomedicine and novel cancer therapy modalities as priority health investment areas, recognizing that next-generation oncology treatments — immunotherapy combinations, targeted delivery systems, radiation enhancement — represent both clinical imperatives (cancer remains a leading cause of death) and commercial opportunities where French companies can compete globally. NBTXR3’s innovative mechanism of action, its hard IP protection (hafnium oxide nanoparticle formulation patents), and its established clinical validation through Phase 2 and Phase 3 trials represent exactly the type of deep-tech health innovation the plan supports.
The Institut National du Cancer (INCa), France’s national cancer agency, has supported Nanobiotix through clinical trial grants and access to the UNICANCER network — a consortium of French cancer centers that enables rapid multi-center clinical trial enrollment. This institutional infrastructure, funded partly through France 2030’s health research investment, is a genuine competitive advantage for French biotech companies in oncology development.
Strategic Position
Nanobiotix occupies a unique competitive position: NBTXR3 is the only approved nanoparticle radioenhancer in the world, and the mechanism of action is sufficiently novel that it requires a separate competitive category rather than simply slot into existing oncology market structures. The most direct competitive comparison is to radiotherapy dose escalation strategies — conventional approaches to improving tumor control by increasing radiation dose — but NBTXR3’s advantage is that it achieves local dose amplification without increasing systemic radiation exposure. In radioresistant tumors (where standard radiotherapy fails because tumor cells repair radiation-induced DNA damage faster than the radiation is delivered), NBTXR3’s acute dose amplification within the tumor overcomes this resistance mechanism.
The commercial opportunity follows from the ubiquity of radiotherapy in oncology: approximately half of all cancer patients receive radiotherapy at some point in their treatment, and NBTXR3’s mechanism applies across multiple solid tumor types treated with radiation. If clinical trials across the multiple ongoing indications succeed, Nanobiotix’s potential market extends to hundreds of thousands of patients annually — a scale that justifies the multi-decade development investment.
Key Technology & Innovation
NBTXR3’s technical innovation is the combination of hafnium oxide’s unique physical properties (high atomic number, creating photoelectric and Compton scattering when irradiated, amplifying local dose) with a nanoparticle formulation engineered for intratumoral injection and long-term tumor retention without systemic dispersion. The particles must remain within the tumor (not diffuse into surrounding tissue or lymphatics), persist for the duration of the radiotherapy course (typically 5-7 weeks), and be cleared safely after treatment completion — each of these requirements demanded specific nanoparticle surface chemistry and size optimization developed over years of preclinical work.
The combination potential is potentially NBTXR3’s most important innovation direction: early clinical data suggests that radiation enhancement combined with immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) may produce synergistic anti-tumor immune responses — effectively using NBTXR3-enhanced radiotherapy as an in-situ tumor vaccine. This combination approach is being tested in several trials and represents a potential mechanism for extending NBTXR3 beyond its current approved indication into the much larger immunotherapy-eligible patient population.
Leadership
Laurent Lévy, the founder, served as CEO through Nanobiotix’s research and early clinical phase before transitioning to Executive Chairman. The company is led by a commercially experienced executive team capable of managing both the complex Janssen partnership and the direct commercialization operations in Europe. The French leadership is based at the Paris headquarters with US commercial operations managed from the company’s New York subsidiary.
Competitive Landscape
Nanobiotix’s competitive position within nanomedicine cancer therapy is relatively uncrowded — the field of nanoparticle-enhanced radiotherapy has few commercial competitors, partly because the development pathway is long and capital-intensive, and partly because regulatory approval for a novel mechanism requires extensive clinical evidence. The more relevant competitive dynamic is at the patient selection level: oncologists choosing between NBTXR3 and alternative approaches (dose escalation, hypoxic sensitizers, immunotherapy combinations) require clinical evidence of meaningful benefit in their specific patient populations.
Caris Life Sciences and Foundation Medicine provide genomic profiling that identifies patients most likely to respond to specific therapies — Nanobiotix’s development of companion diagnostics that identify NBTXR3 responders would significantly strengthen the commercial proposition by enabling targeted patient selection rather than broad population treatment.
Investor Perspective
Nanobiotix’s dual Nasdaq/Euronext listing reflects a mature investor base spanning European institutional investors (who supported the company through early development) and US biotech specialists (who valued the Nasdaq listing for liquidity and analyst coverage). The company’s investment case centers on NBTXR3’s clinical data across multiple indications and the potential for Janssen to exercise options for expanded partnership across additional tumor types.
France 2030’s health innovation support has reduced Nanobiotix’s dependence on purely private capital during its most capital-intensive clinical development phases, providing runway that less well-supported European biotech companies cannot access. For investors, the key variables are NBTXR3 Phase 3 trial outcomes in the larger indication cancers (head and neck, prostate) that would unlock commercial scale, and the Janssen partnership’s evolution as clinical data develops.
Related Companies
- Sanofi — French pharma, biotech peer
- IPsen — French oncology pharma
- OSE Immunotherapeutics — French oncology immunotherapy
- Genfit — French biotech, metabolic disease
- DNA Script — French biotech deep tech
- Median Technologies — French health AI